Brief: Hansa And Sarepta Therapeutics To Initiate Clinical Study With Imlifidase As A Pre-Treatment To Sarepta's Srp-9001 Gene Therapy In Dmd In 2023
02/11/2022 20:32
Nov 2 (Reuters) - Hansa Biopharma AB HNSA.ST :
* HANSA - CO AND SAREPTA THERAPEUTICS TO INITIATE CLINICAL
STUDY
WITH IMLIFIDASE AS A PRE-TREATMENT TO SAREPTA'S SRP-9001 GENE
THERAPY IN DMD IN 2023
* HANSA BIOPHARMA - UNDER TERMS OF AGREEMENT, CO IS ELIGIBLE
FOR A
TOTAL OF UP TO USD 397.5 MLN IN DEVELOPMENT, REGULATORY AND
SALES MILESTONE PAYMENTS.
Source text for Eikon: ID:nWkr85859G
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS